XM does not provide services to residents of the United States of America.

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site</title></head><body>

A round-up of notable broker activity this morning from Europe's top-ranked* analysts:


** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return

** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an end

** Jefferies upgrades German chemicals giant BASF BASFn.DE to "hold" from "underperform", citing more limited earnings risk

** Deutsche Bank cuts AstraZeneca AZN.L to "sell" from "hold", saying it remains materially below mid-term consensus due to concerns on company's future growth

INITIATIONS AND REINSTATEMENTS

** UBS starts Rational RAAG.DE with "neutral" rating and PT of EUR 890, expecting the industrial kitchen retailer's growth to continue in the future

** Barclays starts Swiss real estate companies PSP Swiss Property PSPN.S with "overweight" and Swiss Prime Site SPSN.S with "equal weight", saying cheap debt in Switzerland should help earnings


(*Analyst rankings from Thomson Reuters StarMine. The scale is from 1-star to 5-star with 5 being the best. Analysts are ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods.)



Reporting by Amir Orusov and Clement Martinot

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.